| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Protein SSX2, Cancer/testis antigen 52, CT52, Synovial sarcoma, X breakpoint 2, Tumor antigen HOM-MEL-40, SSX2, SSX2A |
| Entrez GeneID | 6757;727837 |
| WB Predicted band size | 21.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This SSX2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 110-142 amino acids from the Central region of human SSX2. |
+ +
以下是关于SSX2抗体的模拟参考文献示例(内容为虚构，仅供参考)：
---
1. **文献名称**: *SSX2 as a Tumor-Specific Antigen: Serological Detection in Melanoma Patients*
**作者**: Müller et al.
**摘要**: 研究报道了SSX2蛋白在黑色素瘤中的异常表达，并开发了一种基于ELISA的血清抗体检测方法。结果显示，约30%的晚期患者血清中可检测到抗SSX2抗体，提示其可能作为预后标志物。
2. **文献名称**: *Monoclonal Antibody Targeting SSX2 Suppresses Tumor Growth in Xenograft Models*
**作者**: Chen et al.
**摘要**: 研究团队成功制备了靶向SSX2的单克隆抗体(mAb-3F8)，并在肺癌小鼠模型中验证其抗肿瘤活性。抗体通过阻断SSX2与转录调控复合物的相互作用，抑制肿瘤增殖。
3. **文献名称**: *SSX2 Antibody-Based Immunohistochemistry in Prostate Cancer Diagnosis*
**作者**: Sato & Tanaka
**摘要**: 探讨了SSX2抗体在组织病理学中的应用，发现其在转移性前列腺癌活检样本中具有高特异性(92%)，可作为区分原发灶与转移灶的辅助工具。
4. **文献名称**: *Autoantibody Response Against SSX2 in Autoimmune Paraneoplastic Syndromes*
**作者**: González et al.
**摘要**: 分析了SSX2自身抗体在副肿瘤综合征患者中的表达，揭示其与神经肌肉症状的相关性，提示SSX2可能通过分子模拟机制引发交叉免疫反应。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“SSX2 antibody”、“SSX2 cancer immunotherapy”等获取。
The SSX2 antibody targets the SSX2 protein, a member of the SSX (synovial sarcoma X breakpoint) family, which comprises 10 highly homologous genes (SSX1-SSX9 and SSX10). SSX proteins are characterized by an N-terminal KRAB-associated protein 1 (KAP1)-binding domain, involved in transcriptional repression, and a C-terminal divergent region rich in charged amino acids. SSX2 is primarily expressed in germline cells (e.g., testis) under normal conditions but becomes aberrantly upregulated in various cancers, classifying it as a cancer-testis antigen (CTA). Its ectopic expression in tumors, including melanoma, breast, and lung cancers, correlates with malignancy and immune evasion, making it a potential biomarker and therapeutic target.
In oncology, SSX2 is notably implicated in synovial sarcoma, where chromosomal translocation t(X;18) fuses SSX2 with SS18 (SYT), generating an oncogenic fusion protein that disrupts epigenetic regulation. Antibodies against SSX2 are vital tools for detecting this fusion protein in diagnostic assays (e.g., IHC, Western blot) and studying its role in tumorigenesis. They also aid in developing immunotherapies, such as CAR-T cells or vaccines, by identifying SSX2-positive cells for targeted elimination. However, challenges remain due to sequence homology among SSX family members, requiring high-specificity antibodies to avoid cross-reactivity. Research continues to optimize SSX2 antibodies for precision in both basic research and clinical applications.
×
